Literature DB >> 32871692

Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder.

Yan-Ling Zhou1, Feng-Chun Wu1, Cheng-Yu Wang1, Wei Zheng1, Xiao-Feng Lan1, Xiu-Rong Deng1, Yu-Ping Ning2.   

Abstract

BACKGROUND: Evidences suggest that inflammatory marker-mediated neuroplasticity contributes critically to brain changes following antidepressant treatment. To date, no study has examined the relationship between changes in hippocampal volume, depressive symptoms, and inflammatory markers following repeated ketamine treatment.
METHODS: Forty-four patients with major depressive disorder received six intravenous ketamine (0.5 mg/kg) infusions over 12 days. The Montgomery-Asberg Depression Rating Scale (MADRS) was used to assess depressive symptoms, and peripheral blood was collected to test multiple cytokines and tryptophan (TRP) metabolites at baseline, 24 h and 14 days after the sixth infusion (day 13 and day 26). Magnetic resonance imaging (MRI) scans were carried out at baseline and day13, and FreeSurfer software was used to process the T1 images and analyze hippocampal volume.
RESULTS: Following ketamine, a significant improvement in depressive symptoms, a small increase in right hippocampal volume and alterations in inflammatory markers was found. No significant association was found between changes in inflammatory markers and changes in hippocampal volume from baseline to day 13 (P>0.05), while a weak association was found between TRP metabolite changes and other cytokine changes from baseline to day 26 (beta=-0.357, t=-2.600, P = 0.013). LIMITATIONS: The patients continued receiving previous medications during ketamine treatment, which may have impacted hippocampal volume and inflammatory markers.
CONCLUSIONS: Hippocampal volume increase following ketamine was an independent neurobiological effect that was not associated with changes in peripheral inflammatory markers, suggesting a likely complex neurobiological mechanism of the antidepressant effect of ketamine.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hippocampus; Inflammation; Ketamine; Major depressive disorder; Tryptophan

Year:  2020        PMID: 32871692     DOI: 10.1016/j.jad.2020.06.068

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

1.  Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.

Authors:  Gustavo C Medeiros; Todd D Gould; William L Prueitt; Julie Nanavati; Michael F Grunebaum; Nuri B Farber; Balwinder Singh; Sudhakar Selvaraj; Rodrigo Machado-Vieira; Eric D Achtyes; Sagar V Parikh; Mark A Frye; Carlos A Zarate; Fernando S Goes
Journal:  Mol Psychiatry       Date:  2022-06-27       Impact factor: 15.992

Review 2.  The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials.

Authors:  Giordano Novak Rossi; Jaime E C Hallak; Glen Baker; Serdar M Dursun; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-07-13       Impact factor: 5.760

Review 3.  Inflammation-driven brain and gut barrier dysfunction in stress and mood disorders.

Authors:  Ellen Doney; Alice Cadoret; Laurence Dion-Albert; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2021-05-17       Impact factor: 3.698

Review 4.  Gut Microbiota in Depression: A Focus on Ketamine.

Authors:  Alina Wilkowska; Łukasz Piotr Szałach; Wiesław Jerzy Cubała
Journal:  Front Behav Neurosci       Date:  2021-06-23       Impact factor: 3.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.